The Urologic Impact of Guillain–Barré Syndrome

  • Elizabeth V. Dray


Guillain–Barré Syndrome is an acute flaccid paralysis that is rapidly progressing. Neurologic decline continues for 12 hours to 4 weeks after symptom onset. Approximately 25% of patients develop acute urinary symptoms such as difficulty voiding or frank urinary retention. Longer term urinary symptoms include persistent overactive bladder and nocturia. Key urologic interventions include indwelling catheter during acute phase, particularly when patient is experiencing respiratory failure; intermittent catheterization for retention if patient has preserved hand function; voiding trial after neurologic recovery; and anticholinergics for persistent overactive bladder after recovery.


Neurourology Urodynamic studies Guillain–Barré Urinary retention Nocturia 


  1. 1.
    Guillain G. Radiculoneuritis with acellular hyperalbuminosis of the cerebrospinal fluid. Arch Neurol Psychiatr. 1936:975–90.Google Scholar
  2. 2.
    Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yuki N, Hartung H-P. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–304.CrossRefPubMedGoogle Scholar
  4. 4.
    Jacobs BC, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51:1110–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Frontera JA, da Silva IRF. Zika getting on your nerves? The association with the Guillain-Barré Syndrome. N Engl J Med. 2016;375:1581–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Lehmann HC, Hartung H-P, Kieseier BC, Hughes RAC. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10:643–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet (London, England). 2016;388:717–27.CrossRefGoogle Scholar
  8. 8.
    Huizinga R, et al. Innate immunity to campylobacter jejuni in Guillain-Barré Syndrome. Ann Neurol. 2015;78:343–54.CrossRefPubMedGoogle Scholar
  9. 9.
    McGonigal R, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain. 2010;133:1944–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Hafer-Macko CE, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sejvar JJ, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612.CrossRefGoogle Scholar
  12. 12.
    Lichtenfeld P. Autonomic dysfunction in the Guillain-Barré syndrome. Am J Med. 1971;50:772–80.CrossRefPubMedGoogle Scholar
  13. 13.
    van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013;80:1650–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2009;80:56–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Fokke C, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004;148:200–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMedGoogle Scholar
  18. 18.
    van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Ruts L, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75:1439–47.CrossRefGoogle Scholar
  20. 20.
    van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group N Engl J Med. 1992;326:1123–9.Google Scholar
  21. 21.
    Guillain-Barré syndrome Study Group, T. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35:1096–104.CrossRefGoogle Scholar
  22. 22.
    Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1997;63:649–53.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sakakibara R, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barré Syndrome. Neurourol Urodyn. 2009;28:432–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Naphade PU, et al. Prevalence of bladder dysfunction, urodynamic findings, and their correlation with outcome in Guillain-Barre syndrome. Neurourol Urodyn. 2012;31:1135–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010;257:2024–31.CrossRefPubMedGoogle Scholar
  26. 26.
    Amatya, B., Khan, F., Whishaw, M. & Pallant, J. F. Guillain-Barre syndrome: prevalence and long-term factors impacting bladder function in an Australian community cohort.[Erratum appears in J Clin Neurol. 2013;9(4):289–90]. J Clin Neurol. 2013;9:144–50.Google Scholar
  27. 27.
    Wosnitzer MS, Walsh R, Rutman MP. The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barré syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1145–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Elizabeth V. Dray
    • 1
  1. 1.Division of Urology, Department of SurgeryGreenville Health SystemGreenvilleUSA

Personalised recommendations